GSK has recently made a series of major business moves in the biotech market. A slew of transactions involved the pharmaceutical company raising huge funds from the
sale of its remaining stake in Haleon. This sums up to billions of dollars, including notable deals like a $1.5 billion sale and another that netted over $1.5 billion.
Meridian Wealth Management has bought 38,211 shares of GSK, a move that intimates increasing interest from investors. At the same time, a few market days indicated GSK underperforming, whilst several others showed the stock outperforming the market. Interestingly,
GSK executives have also shown confidence in their company's future by investing further into it. Institutional ownership is a whopping 83% with strong Q1 earnings and revenues surpassing estimates. The firm raised profit outlook based on strong vaccine and HIV drug sales. With the sale of Haleon stake nearing its final stages, GSK also witnesses
profits rise, including a whopping 46% YoY rise recorded in Q4 results. However, the company experienced a hiccup when the EU watchdog hindered approval for GSK’s blood cancer drug Blenrep.
GSK Stocks News Analytics from Sat, 29 Jul 2023 07:00:00 GMT to Sun, 19 May 2024 14:59:54 GMT -
Rating 6
- Innovation 2
- Information 7
- Rumor -5
